Enveda Raises $311M at $2B Valuation for AI Drug Discovery

Enveda raised $311 million in Series E funding — late-stage private investment — at a $2 billion valuation, double its value 12 months ago. Reported Sept. 23, led by Catalio Capital Management with Iconiq participating. Founded in 2019 by Viswa Colluru, the clinical-stage biotech uses AI to find drugs from plants and microbes, with multiple candidates in human trials.